Tonix Pharmaceuticals Holding (TNXP) Free Cash Flow (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Free Cash Flow for 17 years, with the latest figure at -$40.8 million in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 165.49% year-over-year to -$40.8 million in Q2 2026; TTM through Jun 2026 was -$158.1 million, a 141.8% decrease from a year earlier, with the FY2025 full-year figure at -$103.2 million, down 69.08% from the prior year.
• Free Cash Flow was -$40.8 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from -$46.1 million in the prior quarter.
• The five-year high for Free Cash Flow was -$9.9 million in Q2 2024, with the low at -$51.3 million in Q1 2022.
• Average Free Cash Flow over 5 years is -$28.2 million, with a median of -$26.1 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 60.66% in 2024, then sank 183.77% in 2025.
• Over 5 years, Free Cash Flow stood at -$27.0 million in 2022, then advanced by 15.55% to -$22.8 million in 2023, then jumped by 35.76% to -$14.6 million in 2024, then tumbled by 183.77% to -$41.5 million in 2025, then gained by 1.79% to -$40.8 million in 2026.
• The last three Free Cash Flow figures came in at -$40.8 million (Q2 2026), -$46.1 million (Q1 2026), and -$41.5 million (Q4 2025), per Business Quant data.